sj-docx-1-msj-10.1177_13524585231221680 – Supplemental material for Longitudinally extensive posterolateral myelitis revealing invasive CNS aspergillosis in an immunocompetent patient

Supplemental material, sj-docx-1-msj-10.1177_13524585231221680 for Longitudinally extensive posterolateral myelitis revealing invasive CNS aspergillosis in an immunocompetent patient by Lina Jeantin, Delphine Leclercq, Suzanne Tran, Elisabeth Maillart, Vincent Reina, Arnaud Fekkar, Fanny Lanternier, Clémence Marois and Adam Celier in Multiple Sclerosis Journal</p

Major MRI Response in patient 2.

<p>Major MRI response in Patient 2 with disappearance of periachillean tissular infiltration and of talus bone edema. Slight talus contrast enhancement persistance on T1 Gado Fat Sat sequence.</p

Organ involvement in patients 4 and 5.

<p>Lumbar tumefaction with draining sinuses (A). Black grains drainage (B). Paraspinal abdominal eumycetoma extension on abdomen MRI LAVA sequence (C) and lung extension on lung CT scanner (D) in patient 5. Clinical (E) second and third metatarsal destruction on 3D reconstruction CT (F) of foot. Foot mycetoma aspect on Axial T1 Fat Sat Gadolinium MRI (G) and PET/CT (H) in patient 4.</p

Treatment and outcome characteristics of eleven patients with eumycetoma.

<p>B: Bone involvement; CPK: creatinine phosphokinase; CR: Complete Response; D: drainage; I: inflammation; ITZ: itraconazole; J: Joint involvement; KTZ: ketoconazole; M: Muscle involvement; Node involvement; P: pain; PCZ: posaconazole; PF: Primary failure; PR: Partial Response; R: relapse; S: soft tissue involvement; SUV: Standard Uptake Value; V: Visceral involvement; VCZ: voriconazole.</p><p>* Patient 8 only had one post last generation triazole treatment dosage of BG so that evolution couldn’t be assessed.</p><p>Treatment and outcome characteristics of eleven patients with eumycetoma.</p

Major MRI and PET/CT responses in Patient 9.

<p>Left foot T1 Fat Sat Gadolinium enhanced MRI (A): Disappearance of periachillean tissular infiltration with the dot in the circle pattern, talus bone edema disappearance and slight talus contrast enhancement persistence. Disappearance of talus and tarsal hypermetabolism on left foot PET/CT (B).</p

Primer positions are indicated from the c-Kit sequence published through the NCBI accession number X06182.

<p>Primer positions are indicated from the c-Kit sequence published through the NCBI accession number X06182.</p

Relationship between phenotype and genotype in patients with mastocytosis according to their age of onset.

<p>Data are expressed in number (percentage).</p

Exons 8 through 13 and 17 mutations according to mastocytosis age of onset.

<p>Data are expressed in number (percentage), 816: substitution of valine in 816 codon of <i>c-kit</i>, Other mutations: mutation in exons 8 through 13. WT: absence of mutation in exons 8 through 13 and 17. Complete genotype was not available for 4 816 WT patients; 1 patient in group 1A, 1 in group 1B and 2 in group 2.</p

Description of 5 adult patients with mastocytosis not related to 816 c-kit mutation.

<p>Description of 5 adult patients with mastocytosis not related to 816 c-kit mutation.</p